Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target Lowered to $1.50 at Wells Fargo & Company
Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) had its price objective decreased by Wells Fargo & Company from $2.00 to $1.50 in a report issued on Friday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biotechnology company’s stock. Several other brokerages have also recently issued reports on ADAP. Mizuho reduced […]
Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) had its price objective decreased by Wells Fargo & Company from $2.00 to $1.50 in a report issued on Friday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biotechnology company’s stock. Several other brokerages have also recently issued reports on ADAP. Mizuho reduced […]
